A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin)
Latest Information Update: 12 May 2022
At a glance
- Drugs Metformin/sitagliptin (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 29 Jun 2021 Results of a pooled analysis comparing the characteristics of younger (Y, 10-14 yrs) vs. older (O, 15-17 yrs) patients in global clinical trials of sitagliptin as initial oral therapy (IOT, NCT01485614) or as add-on to metformin therapy (AMT, NCT01472367, NCT01760447). presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 26 Sep 2019 Status changed from active, no longer recruiting to completed.